A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
about
Nanomedicine and drug delivery strategies for treatment of inflammatory bowel diseaseShining a light on intestinal trafficReview article: anti-adhesion therapies for inflammatory bowel diseaseBoswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical dataMeta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.Antisense approach to inflammatory bowel disease: prospects and challenges.A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice.Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.DNA and RNA derivatives to optimize distribution and deliverySystematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.Emerging drugs for the treatment of ulcerative colitisAlicaforsen therapy in inflammatory bowel disease.Evolving knowledge and therapy of inflammatory bowel disease.Target mRNA inhibition by oligonucleotide drugs in man.Emerging biological treatments in inflammatory bowel diseases.Antisense oligonucleotides: from design to therapeutic application.Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion moleculesUpdate in the treatment of paediatric ulcerative colitis.The intestinal microvasculature as a therapeutic target in inflammatory bowel disease.Recent understanding of IBD pathogenesis: implications for future therapies.Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.Treatment of inflammatory bowel disease: a review of medical therapy.Biologic targeting in the treatment of inflammatory bowel diseases.Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Current and future therapies for inflammatory bowel disease.Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.Targeting T-cell migration in inflammatory bowel disease.Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.Review article: strategies for the management of chronic unremitting ulcerative colitis.New biologic therapeutics for ulcerative colitis and Crohn's disease.Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis.Alicaforsen for the treatment of inflammatory bowel disease.Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells.Antisense oligonucleotide technologies in drug discovery.Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.
P2860
Q26777400-E4C07F1A-E77D-405E-B71C-9E1C928CF59EQ26863227-579AF345-A0E8-4EB2-BA9F-70A6B39C0F88Q26999705-EE1E9B90-A777-436A-A7F3-DEEB1C9F5331Q28237079-406F664E-3B60-4F90-9DF1-439128FE8354Q30644152-0C01AC77-22B7-4363-81EC-6A501EF56BE0Q34473572-6A193401-6531-465C-A9B5-84406E82EE0CQ34521106-C064DA19-4D3D-404B-AE25-3B38E849EFF6Q35049145-17B797ED-DC9A-4293-8C52-CA18480BFB88Q35637379-BF4C6D78-225A-46D7-A249-E2C6480F6191Q35761406-35A6D267-6470-4DA6-8025-3407A13333FCQ35858691-0FA2B00C-2756-4656-AB9C-2B25297AE985Q35889006-63F40BF6-C6AC-40DC-ACF7-FB2A478E96AEQ36039436-050C22CA-2877-40D2-A8D4-B02BCB403277Q36273416-26410E99-B7CC-4774-B2F4-B68D87E9BADDQ36414506-6FAC6910-E4FC-4219-B1A2-C03AD85B2B9FQ36435109-99833111-C13C-40A1-9ABE-F03F02D14603Q36478109-AC69AB03-58BA-4700-873C-B137884AE2E3Q36478849-24CE0E47-D994-4FB5-8714-9D9B166E0F68Q36579737-AE6EACB6-7B23-4C8D-9086-2CFF7C79A23CQ36613876-7FB3111F-C409-4850-A817-3D4A12B60842Q36631424-29A139CB-2AB8-487C-863A-B2B9816C3008Q36639759-B1DAD967-A660-4CFD-AA5A-284F533A21A1Q36918516-DB338DDC-C0B9-4856-894A-399B1D9E2FA1Q37058862-05138791-DB12-400C-A100-79894FDCDA6BQ37303206-0866B093-6C53-4313-A62C-7F9322F68D3FQ37321859-B7A93BA2-6B3D-4C73-83C6-62B331AFB869Q37346047-24D3885E-8F23-4938-8362-71C51D2C053EQ37419563-69336A2B-D0DF-4EE5-9063-78A931852313Q37680981-9E6CB891-F41F-419B-9183-7A496B556C39Q38040430-2EE2D7B9-2309-4AE8-88EA-A407858E955CQ38053495-04C3D5CB-C1A4-4A6A-A639-6AB0A3222B63Q38110317-57FDC844-22D2-4F17-8F1E-3968465768EEQ38185687-C514E3A3-71CF-41C6-AAF3-F311DC132D1CQ38351464-494145D4-13D5-4B17-9293-A721DF46EF9CQ38505808-5E005DC4-F525-4647-AC67-81D5673DD315Q38697244-0F6B858C-A24C-4A67-8B0F-4BFA0128DC1DQ38992068-0EF16C3E-091F-46CA-AD9C-D7BFEAE1E318Q40111828-2D694633-1B1D-45AC-9391-9A21F55D7975Q40292829-088CF03A-27B2-41CA-A2ED-99886F82078DQ42245018-9C249317-47C7-4C4A-9DF6-051F65E28DB5
P2860
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A randomised, controlled, doub ...... in active ulcerative colitis.
@ast
A randomised, controlled, doub ...... in active ulcerative colitis.
@en
type
label
A randomised, controlled, doub ...... in active ulcerative colitis.
@ast
A randomised, controlled, doub ...... in active ulcerative colitis.
@en
prefLabel
A randomised, controlled, doub ...... in active ulcerative colitis.
@ast
A randomised, controlled, doub ...... in active ulcerative colitis.
@en
P2093
P2860
P356
P1433
P1476
A randomised, controlled, doub ...... in active ulcerative colitis.
@en
P2093
S J H van Deventer
P2860
P304
P356
10.1136/GUT.2003.036160
P407
P577
2004-11-01T00:00:00Z